CME/CE

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying acromegaly, interpreting clinical findings, and selecting appropriate management strategies based on patient presentation. Through guided questions and expert-informed discussion, learners gain insight into the real-world application of evidence-based approaches.

This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not screened. Learn practice strategies to help close preventable gaps in care, including identifying risk during routine visits, addressing patient concerns, ordering appropriate screening, and ensuring follow-up for findings such as pulmonary nodules.

Bronchiectasis is a chronic, progressive respiratory disease that is characterized by accelerated lung function decline and impaired quality of life, yet it remains substantially under recognized and underdiagnosed in routine practice. High-resolution computed tomography is the cornerstone of diagnosis, but early and subtle radiologic manifestations are frequently overlooked or misattributed to aging, infection, or nonspecific small airway disease. Radiologists occupy a pivotal position as the earliest decision-makers in the bronchiectasis care pathway, so it is imperative that they can identify bronchiectasis accurately and early to ensure timely referral to specialized care for evidence-based therapy.

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.